Verastem Faces Volatility: State Street Invests Amid Cancer Drug PushVerastem’s stock volatility, State Street’s 4% stake, and its RAF/MEK/FAK cancer drug pipeline reveal a biotech firm at a pivotal crossroad.VERASTEM INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 12/11/2026, 21:33 3 minutes to read
Verastem Q3 2026 Results: Revenue Misses, Future Financing Set to Extend Runway to 2028Verastem Q3 2026 results miss forecasts but outlines a $250 m financing plan to boost cash through 2028, sparking analyst upside on its cancer‑drug pipeline.VERASTEM INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 08/11/2026, 03:35 3 minutes to read